Converting a tumor from checkpoint blockade-resistant to checkpoint blockade-sensitive: Immunotransplant for aggressive lymphoma.

被引：0
|
作者：
Marshall, Netonia
Hammerich, Linda
Upadhyay, Ranjan
Marron, Thomas Urban
Brody, Joshua
机构：
[1] Mt Sinai Hosp, Ichan Med Sch, New York, NY USA
[2] Icahn Sch Med Mt Sinai, New York, NY USA
[3] Mt Sinai Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e14538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14538
引用
收藏
页数：2
相关论文
共 39 条
  • [31] Tumor microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in cervical cancer: An exploratory biomarker analysis from SKYSCRAPER-04 (SKY04) study
    Krishnan, Venkatesh
    Chang, Ching-Wei
    Bader, Elyssa
    Salani, Ritu
    Monk, Bradley J.
    Kim, Yong-Man
    Ghamande, Sharad
    Hall, Shaundra L.
    Lorusso, Domenica
    Barraclough, Lisa
    Gilbert, Lucy
    Ramirez, Adrian Guzman
    Lu, Chien-Hsing
    Berton, Dominique
    Colombo, Nicoletta
    Castro, Marcela
    Lin, Yvonne G.
    McCormack, Mary
    Molinero, Luciana
    CANCER RESEARCH, 2024, 84 (06)
  • [32] The Prognostic Impact of Tumor Microenvironment and Checkpoint Blockade-Associated Molecules (PD-1, PD-L1, CD163 and CD14) in Nodal Diffuse Large B-cell Lymphoma, NOS
    Ömer Atmış
    Nalan Neşe
    İsmet Aydoğdu
    İlknur Alaca
    Hanife Seda Mavili
    Aydın İşisağ
    Indian Journal of Hematology and Blood Transfusion, 2024, 40 : 340 - 345
  • [33] The Prognostic Impact of Tumor Microenvironment and Checkpoint Blockade-Associated Molecules (PD-1, PD-L1, CD163 and CD14) in Nodal Diffuse Large B-cell Lymphoma, NOS
    Atmis, Omer
    Nese, Nalan
    Aydogdu, Ismet
    Alaca, Ilknur
    Mavili, Hanife Seda
    Isisag, Aydin
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024, 40 (02) : 340 - 345
  • [34] Combination Therapy Using Adoptively Transferred T-Cells from Tumor-draining Lymph Nodes and Checkpoint Blockade, Chemotherapeutic, and Immune-modulating Agents Improve Therapeutic Efficacy in a Syngeneic Murine Model
    Lyons, J. L.
    Zhang, M.
    Senders, Z.
    Kim, J.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S130 - S130
  • [35] PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer
    Negrao, Marcelo V.
    Lam, Vincent K.
    Reuben, Alexandre
    Rubin, Maria Laura
    Landry, Lara Lacerda
    Roarty, Emily B.
    Rinsurongkawong, Waree
    Lewis, Jeff
    Roth, Jack A.
    Swisher, Stephen G.
    Gibbons, Don L.
    Wistuba, Ignacio I.
    Papadimitrakopoulou, Vassiliki
    Glisson, Bonnie S.
    Blumenschein, George R., Jr.
    Lee, J. Jack
    Heymach, John V.
    Zhang, Jianjun
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1021 - 1031
  • [36] CHECKPOINT BLOCKADE HASTENS A SWITCH FROM AN NKT DOMINANT, TNF-ALPHA-DRIVEN TO A CD4+/CD8+IFN-GAMMA-DRIVEN IMMUNE RESPONSE WITHIN MC38 TUMOR-INFILTRATING LYMPHOCYTES
    Aoyama, Shota
    Nakagawa, Ryosuke
    Nemoto, Satoshi
    Villarroel, Patricio Perez
    Mule, James
    Mailloux, Adam
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A134 - A135
  • [37] An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
    Galvao, V.
    Palomero, J.
    Creus-Gonzalez, I.
    Lostes Bardaji, M. J.
    Lozano-Rabella, M.
    Garcia-Garijo, A.
    Yuste, A.
    Rodriguez, L.
    Villalobos Alberu, X.
    Rotxes, M.
    Vieito Villar, M.
    Santa Gadea, O. Saavedra
    Alonso, G.
    Brana, I.
    Munoz-Couselo, E.
    Querol, S.
    Tabernero, J.
    Martin-Lluesma, S.
    Gros, A.
    Garralda, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S650 - S650
  • [38] Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) plus ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
    Ramalingam, Suresh S.
    Hellmann, Matthew D.
    Awad, Mark M.
    Borghaei, Hossein
    Gainor, Justin
    Brahmer, Julie
    Spigel, David R.
    Reck, Martin
    O'Byrne, Kenneth J.
    Paz-Ares, Luis
    Zerba, Kim
    Li, Xuemei
    Geese, William J.
    Green, George
    Lestini, Brian
    Szustakowski, Joseph D.
    Chang, Han
    Ready, Neal
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma.
    Barth, M. J.
    Hernandez-Ilizaliturri, F. J.
    Mavis, C.
    Tsai, P.
    Gibbs, J. F.
    Czuczman, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
1234